NCT06971380View on ClinicalTrials.gov

Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

May 15, 2028

Study Completion Date

May 15, 2030

Conditions
Multiple Myeloma, Refractory to Standard TreatmentMultiple Myeloma, RelapsedLight Chain Amyloidosis
Interventions
BIOLOGICAL

HBI0101 CART

HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The HBI0101 CART may be provided fresh or cryopreserved.

Trial Locations (1)

9574869

RECRUITING

Hadassah MO, Jerusalem

All Listed Sponsors
lead

Polina Stepensky

OTHER